SAN DIEGO--(BUSINESS WIRE)--June 7, 2006--Nereus Pharmaceuticals, Inc., a pioneer in drug discovery and development from marine microbial sources, has initiated a Phase I clinical trial to evaluate the safety and tolerability of NPI-2358, a novel, small molecule tumor vascular disrupting agent (VDA) for the treatment of patients with solid tumors.
